The cAMeLot-2 study is testing how safe and effective a study medication is for people with a particular type of newly diagnosed acute myeloid leukemia (AML).
You may be considered for the cAMeLot-2 study if you have newly diagnosed AML and are not able to receive certain stronger forms of chemotherapy. You also need to have AML with a mutation (a genetic change) in either the KMT2A or NPM1 gene.
All participants in the study will receive the two standard therapies for your type of AML. In addition to the standard therapies, participants will be randomly assigned to also receive either the study medication or a placebo (an inactive substance that looks like the study medication).
The goal of the study is to learn more about how the study medication may affect AML when taken with two approved drugs that are the standard treatment for newly diagnosed AML.
- The study will enroll patients who cannot receive strong chemotherapy.
- Doctors hope this research may help other people with similar conditions in the future.
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (spongy areas within the bone that produce blood cells), where the body makes too many abnormal white blood cells. These abnormal cells crowd out healthy ones, which can lead to symptoms like often feeling tired, infections, and bruising.
Participants will take the study treatments on a schedule that repeats about every 28 days. This is called a study cycle. You will have 8 clinic visits during the first cycle and 1 to 2 clinic visits for all other cycles.
Contact us
Ready to learn how you can get connected to a clinical trial site? Complete this form with the required (*) fields below and we will reach out to you within one business day using the email address you provide.
Please keep in mind: Even if you believe you meet the eligibility criteria, joining a clinical trial is not guaranteed. Whether you’re referred or able to take part depends on a review by a qualified healthcare professional. This contact us form is intended for United States participants only.
Note about privacy: Email responses may not be encrypted. This means there’s a chance that messages could be seen by someone other than the intended recipient. We will avoid including sensitive personal information in emails whenever possible. However, we cannot guarantee that no sensitive information will be revealed indirectly.